Endovastec™ recently announced the first commercial use of its Talos™ Thoracic Stent Graft System (Talos™) in Argentina. The procedure was performed by Dr. Marcelo Bettinotti, Dr. Sebastian Peralta, and their team at Sanatorio Güemes Hospital in Buenos Aires, Argentina.

The patient, a 40-year-old male, was diagnosed via CTA with a Stanford type B aortic dissection extending into the abdominal aorta. Standard stent grafting posed a risk of inadequate organ perfusion, while the use of multiple stents could increase the risk of spinal ischemia and paralysis.

Based on preoperative imaging and measurements, the clinical team developed a personalized solution utilizing a single Talos™ stent graft combining a 160 mm covered segment with a 60 mm honeycomb-design segment. This approach effectively sealed both the proximal and distal entry tears, restored perfusion to the true lumen, and preserved blood flow to intercostal arteries, thereby reducing the risk of spinal cord injury.

Following the procedure, Dr. Bettinotti praised the system for its deliverability in complex anatomies and its stepwise deployment mechanism, which enables precise and controlled placement.

Talos™ is a next-generation straight thoracic stent graft system, and the world’s first “breathing” stent graft specifically designed for the treatment of Stanford type B aortic dissection. It has been approved for clinical use in multiple countries and is currently deployed in more than 400 hospitals worldwide. This milestone follows the first clinical use of Talos™ in South America, which took place in Brazil shortly before the Argentina case.